Vantage logo

Amarin falls at obvious hurdle

Amarin’s loss of a crucial patent lawsuit shows that potential buyers were right to be wary of the Vascepa opportunity.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.